NCT01812148

Brief Summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

March 12, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 18, 2013

Completed
Last Updated

March 18, 2013

Status Verified

March 1, 2013

Enrollment Period

1.2 years

First QC Date

March 12, 2013

Last Update Submit

March 15, 2013

Conditions

Peritoneal Mesotheliomas

Keywords

Peritoneal Mesotheliomashyperthermic intra-peritoneal chemotherapy (HIPEC)OxaliplatinCytoreductive surgeryOxaliplatin HIPEC

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    5 years

Secondary Outcomes (1)

  • Disease-Free survival

    5 years

Study Arms (1)

Peritoneal Mesotheliomas

Cytoreductive surgery and HIPEC

Procedure: Cytoreductive surgery and HIPEC

Interventions

Cytoreductive surgery and HIPECPROCEDURE

Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Peritoneal Mesotheliomas

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering of peritoneal mesotheliomas undergoing cytoreductive surgery and HIPEC

You may qualify if:

  • Peritoneal mesothelioma

You may not qualify if:

  • Non resectable disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maisonneuve Rosemont Hospital

Montreal, Quebec, H1T 2M4, Canada

Location

MeSH Terms

Interventions

Cytoreduction Surgical ProceduresHyperthermic Intraperitoneal Chemotherapy

Intervention Hierarchy (Ancestors)

Surgical Procedures, OperativeChemotherapy, AdjuvantCombined Modality TherapyTherapeuticsDrug TherapyHyperthermia, Induced

Study Officials

  • Lucas Sideris, MD

    Maisonneuve-Rosemont Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

March 12, 2013

First Posted

March 18, 2013

Study Start

January 1, 2012

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

March 18, 2013

Record last verified: 2013-03

Locations

CA(1)